Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life and few show cardiovascular benefits at one year, finds an analysis of the latest evidence published by The BMJ today.

Over-the-counter antihistamines and a prescription anti-inflammatory drug both have a small benefit in reducing long Covid fatigue among people receiving care from specialist long Covid clinics, according to new findings from a large clinical trial led by UCL (University College London) and UCLH.

Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding use of obesity drugs for weight loss treatment. The statement, which is published in The Lancet Diabetes & Endocrinology, is led by Dr Laurence Dobbie of the Department of Population Health Sciences, King’s College London, with an international team of 26 authors.

Two journals specialising in reporting on the links between biology and mental health have reported significant increases in the number of times articles have been cited by scientists. The editors cite technical improvements, but also growing interest in the biological basis of mental health processes as the likely reasons.